Search for a trial

A Multicenter, Phase 1/1b Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors

The purpose of this study is to evaluate how safe telisotuzumab vedotin is and how telisotuzumab vedotin is tolerated as monotherapy and in combination with osimertinib.

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

This study has been transitioned to CTIS with ID 2023-505749-14-00 check the CTIS register for the current data. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab…